Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

KalVista Pharmaceuticals, Inc. - Common Stock (NQ:KALV)

14.52 -0.99 (-6.38%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about KalVista Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
KalVista Pharmaceuticals Announces Pricing of a $160.1 Million Public Offering of Common Stock and Pre-Funded Warrants
From KalVista Pharmaceuticals, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
KalVista Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Insiders Buying Dorian LPG And 2 Other Stocks
Although U.S. stocks closed lower on Tuesday, there were a few notable insider trades. 
Via Benzinga
KalVista Pharma: Q2 Earnings Insights
Via Benzinga
Citigroup To Rally Over 19%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
What's Going With Hereditary Angioedema-Focused KalVista Pharmaceuticals Stock On Tuesday?
Results from KalVista Pharmaceuticals' Phase 3 KONFIDENT trial. Sebetralstat, an oral on-demand therapy, shows efficacy for hereditary angioedema. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
KalVista Pharmaceuticals Reports Phase 3 KONFIDENT Trial Meets All Endpoints for Sebetralstat as First Oral On-demand Therapy for Hereditary Angioedema
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Insiders Buying Monro And 3 Other Stocks
Although U.S. stocks closed higher on Thursday, there were a few notable insider trades. 
Via Benzinga
$10M Bet On ArriVent BioPharma? Check Out These 4 Stocks Insiders Are Buying
Although U.S. stocks closed higher on Thursday, there were a few notable insider trades. 
Via Benzinga
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Over $1M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying
Although U.S. stocks closed higher on Monday, there were a few notable insider trades. 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
$230M Bet On Talos Energy? Check Out These 4 Stocks Insiders Are Buying
Although U.S. stocks closed higher on Friday, there were a few notable insider trades. 
Via Benzinga
Insiders Buying KalVista Pharmaceuticals And 3 Other Stocks
Although U.S. stocks closed higher on Wednesday, there were a few notable insider trades. 
Via Benzinga
$6.5M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying
Although U.S. stocks closed slightly higher on Friday, there were a few notable insider trades. 
Via Benzinga
Around $2.4M Bet On HighPeak Energy? Check Out These 4 Stocks Insiders Are Buying
Although U.S. stocks closed lower on Friday, there were a few notable insider trades. 
Via Benzinga
KalVista Pharmaceuticals Announces Publication of First Oral Factor XIIa Data in Frontiers in Pharmacology
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KALV Stock Earnings: KalVista Pharma Misses EPS for Q2 2024
KALV stock results show that KalVista Pharma missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
KalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational Update
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From KalVista Pharmaceuticals, Inc.
Via Business Wire
3 Micro-Cap Stocks That Could Be Moonshots
If you are hungry for high-risk returns, then these micro-cap stocks to buy could be your winning ticket to future yields. 
Via InvestorPlace
KalVista Pharmaceuticals Presents Real-World Data at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals Announces Phase 3 KONFIDENT Trial Milestone Achieved
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals to Present Data at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals Presents Data on HAE Attacks in Patients Receiving Long-Term Prophylaxis at the Asia Pacific Association of Allergy, Asthma and Clinical Immunology 2023 International Conference
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From KalVista Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS